Generic Name and Formulations:
Phenoxybenzamine HCl 10mg; caps.
WellSpring Pharmaceuticals, Corp.
Indications for DIBENZYLINE:
Treatment of pheochromocytoma, to control episodes of hypertension and sweating. May use concomitant β-blocker if tachycardia is excessive.
Individualize. Initially 10mg twice daily. Increase dose every other day, usually to 20–40mg 2 or 3 times daily, until optimal dose obtained. Observe patients after each increase before instituting another increase.
Conditions where a fall in BP may be undesirable.
Cerebral or coronary arteriosclerosis. Renal damage. May aggravate respiratory infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant drugs that stimulate both alpha- and beta-adrenergic receptors (eg, epinephrine) may produce exaggerated hypotensive response and tachycardia. Blocks hyperthermia production by levarterenol. Blocks hypothermia production by reserpine.
Alpha adrenergic blocker.
Postural hypotension, tachycardia, inhibition of ejaculation, nasal congestion, miosis, GI upset, drowsiness, fatigue. May be carcinogenic (w. long-term use: not recommended).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA Fast-Tracks Treatment for Autism Spectrum Disorder
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics